Veeva Systems, a leading cloud software provider for life sciences, is expected to report strong Q3 earnings on August 26, 2026, with analysts projecting revenue of about $905 million and EPS of $2.22, an 11.6% increase year-over-year. The company benefits from recent business wins like Biogen's global adoption of Veeva's Vault CRM platform, which supports unified commercial operations and faster medicine delivery. Veeva's strong financial health is highlighted by a low debt-to-equity ratio and high liquidity, and it has a history of surpassing earnings estimates, suggesting potential continued growth in the life sciences software market.
Capital One experienced a significant 26% increase in purchase volume, highlighting strong growth in its recent franchise acquisition. In contrast, the legacy Discover card volume saw minimal growth, rising less than 2%. This disparity underscores th...
The Bushido Capital US Equity ETF (SMRI) receives a Hold rating from analyst Vasily Zyryanov. The fund shows a strong mix of growth at a reasonable price (GARP) and quality factors, with a low PEG ratio of 0.75 and a 5.4% earnings yield. Despite a ye...
BlackRock's head of digital assets, Robert Mitchnick, highlights the growing US federal debt exceeding $40 trillion and rising interest payments as key reasons Bitcoin's investment appeal is strengthening. He argues that as government fiscal health w...
AAVE trades at $128.38 on August 26, 2026, recovering above its 50-day and 200-day moving averages after a 46.5% gain in the past week. Despite this rebound, the coin remains 61.8% below its 12-month high of $336.27 and shows signs of being overbough...
Veeva Systems, a cloud software provider for life sciences, is rated a buy due to strong double-digit revenue growth, expanding profitability, and a solid, low-debt balance sheet. Its subscription model delivers high margins, with Q1 FY2027 showing 7...
